Innate Pharma 1 article

Innate Pharma brings innate immune oncology and ANKET multispecific NK cell engagers into the same corporate research profile, characteristic of a biopharmaceutical company. The scientific portfolio of Innate Pharma brings together natural killer cell activation, lacunatamab anti-KIR3DL2 antibody and cutaneous T-cell lymphoma immunotherapy, preserving a specific mechanistic identity. A complementary company-level marker is innate immune oncology in the profile of Innate Pharma.

Clinical Trials & Evidence

October 8, 2026, 1:26 PM · 4 mins read

Over one hundred firms race to develop new NK cell lymphoma drugs

Clinical trials for natural killer cell lymphoma are ramping up, with more than one hundred companies and over 140 experimental drugs now in play. Novel immunotherapies and combination treatments are reshaping the field.